Similarly, metabolism switches to glycolysis and lipid accumulation from fatty acid utilization in DKD, SGLT2 inhibitors can correct metabolic disorders by reducing HIF-1α levels [150]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.